cdc.gov/coronavirus

ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

October 21, 2021
Daily trends in number of COVID-19 cases in the United States 

CDC. https://covid.cdc.gov/covid-data-tracker/#trends_dailycases. Accessed October 19, 2021

January 23, 2020 – October 17, 2021

44,857,861 total cases

2

Current 7-day average for cases: 

75,571
Daily trends in the number of COVID-19 deaths in the United States

CDC. https://covid.cdc.gov/covid-data-tracker/#trends_dailydeaths. Accessed October 19, 2021

January 23, 2020 – October 17, 2021

Current 7-day average for deaths: 

1,093

3

726,206 total deaths
 Considerations for booster doses of COVID-19 vaccines

– Real-world vaccine effectiveness studies (U.S. and abroad)

– RCT safety and immunogenicity of booster doses 

– NIH Mix and match study 

– GRADE of booster evidence

– EtR: implementation, values, acceptability, resource use, equity

 Reviewing data for pediatric COVID-19 vaccines

– SARS-CoV-2 seropositivity in children 

– Pediatric COVID-19 epidemiology

COVID-19 Work Group activities – September/October 2021

4
• Individuals 65 years of age and older;

• Individuals 18 through 64 years of age at high risk of severe COVID-19; and

• Individuals 18 through 64 years of age with frequent institutional or occupational 

exposure to SARS-CoV-2

FDA expanded Moderna COVID-19 vaccine EUA to include a single booster dose, 

to be administered at least six months after completion of the primary series in:

Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines | FDA

FDA expanded Janssen COVID-19 vaccine EUA to include a single booster dose, 

to be administered at least two months after completion of the primary series 

for individuals ≥18 years of age

FDA amended the EUAs to allow for the use of each available COVID-19 vaccine 

as heterologous (or “mix and match”) booster dose in eligible individuals 

following completion of primary vaccination with a different COVID-19 vaccine
 Moderna: Booster dose data Dr. Miller (Moderna)

 Janssen: Booster dose data Dr. Heaton and Dr. Douoguih (Janssen)

 NIH Mix and Match booster dose study Dr. Atmar (Baylor College of Medicine)

Break

 PUBLIC COMMENT

 v-safe and VAERS: Third dose and simultaneous vaccination Dr. Hause (CDC)

 Vaccine safety updates Dr. Shimabukuro (CDC)

 Myocarditis updates: VAERS Dr. Su (CDC)

 Myocarditis: VSD Dr. Klein (KPNC)

 VaST summary Dr. Talbot (VaST Chair)

Break

Agenda: Thursday, October 21, 2021
 COVID-19 vaccine effectiveness, primary series Dr. Jones (CDC)

 Evidence to Recommendations Framework Dr. Dooling (CDC)

 Clinical considerations Dr. Reddy (CDC)

 Policy questions Dr. Dooling (CDC)

 Discussion

VOTE

 Moderna COVID-19 vaccine booster dose

 Janssen COVID-19 vaccine booster dose

Agenda: Thursday, October 21, 2021
ACIP members

 Matthew Daley (chair)

 Beth Bell 

 Grace Lee

 Keipp Talbot

 Oliver Brooks

Ex-officio/government members

 FDA: Doran Fink, Rachel Zhang

 NIH: Chris Roberts

 IHS: Thomas Weiser, Uzo Chukwuma

 DOD: Bryan Schumacher

 CMS: Jeff Kelman

 BARDA: Christine Oshansky

 HHS: David Kim

CDC Leads

 Sara Oliver

 Kathleen Dooling

Work group members

8

Liaisons

 AAFP: Jonathan Temte

 AAP: Sean O’Leary

 ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

 ACP: Jason Goldman

 AGS: Ken Schmader

 AIM: Rob Shechter (primary), 

Jane Zucker (alternate)

 AMA: Sandra Fryhofer

 ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

 APhA: Michael Hogue

 ASTHO: Marcus Plescia

 CSTE: Susan Lett (primary), 

Christine Hahn (alternate)

 IDSA: Jeff Duchin (primary), 

Carol Baker (alternate)

Liaisons, cont’d

 NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

 NACI: Matthew Tunis 

 NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

 NMA: Patricia Whitley-Williams

 SHEA: Marci Drees

Consultants

 Ed Belongia 

 Kathy Kinlaw 

 Dayna Matthew 

 Kathleen Neuzil 

 Stanley Perlman 

 Peter Szilagyi

 Jose Romero
 Sarah Mbaeyi

 Mary Chamberland

 Amanda Cohn

 Julia Gargano

 Jack Gersten

 Monica Godfrey

 Stephen Hadler

 Danielle Moulia

 Heidi Moline

 Megan Wallace

 Jennifer Collins

 Sujan Reddy

CDC participants

9

 Jefferson Jones

 Edwin Shanley

 Rita Helfand

 Cynthia Jorgensen

 Megan Lindley

 Nicole Lindsey

 Ruth Link-Gelles

 Jessica MacNeil

 Lauri Markowitz

 Jean Cox-Ganser

 Meredith McMorrow

 Amy Blain

 Andrew Kroger

 Melinda Wharton

 Kate Woodworth

 Yon Yu

 Kristin Nordland

 Kevin Chatham-Stevens

 Erin Tromble

 Dana Meaney-Delman

 Thomas Clark

 Sam Graitcer

 Lisa Grohskopf

 Anthony Fiore

 Rebecca Morgan

 Titilope Oduyebo

 Hannah Rosenblum

 Heather Scobie

 Edwin Shanley

 Tom Shimabukuro

 Natalie Thornburg

 Ian Plumb

 Thomas Clark

 Doug Campos-Outcalt

 Jillian Doss-Walker
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!